BioStock: Status report CombiGene - In the front line of gene therapy

In recent years, gene therapies have emerged as one of the hottest areas within life science and the temperature is rising as the first treatments are now available to patients in the US and Europe. During the 2020s, several new therapies are expected to be marketed, a breakthrough period for these therapies that through one or a few treatments have the potential not only to relieve but to cure diseases. The attention focused on gene therapies has lately resulted in several acquisitions and licensing deals. On the Swedish stock market, there is only one listed gene therapy company, CombiGene. BioStock has now published a status report of the company, which can be downloaded below.

Read the full CombiGene status report at biostock.se:

https://www.biostock.se/en/status-report-combigene-in-the-front-line-of-gene-therapy/

This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/